Literature DB >> 9694719

Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.

L Krenacs1, A W Himmelmann, L Quintanilla-Martinez, T Fest, A Riva, A Wellmann, E Bagdi, J H Kehrl, E S Jaffe, M Raffeld.   

Abstract

The paired box containing gene PAX-5 encodes the transcription factor BSAP (B-cell-specific activator protein), which plays a key role in B-lymphocyte development. Despite its known involvement in a rare subtype of non-Hodgkin's lymphoma (NHL), a detailed examination of BSAP expression in NHL has not been previously reported. In this study, we analyzed normal and malignant lymphoid tissues and cell lines, including 102 cases of B-cell NHL, 23 cases of T- and null-cell NHL, and 18 cases of Hodgkin's disease. Normal lymphoid tissues showed strong nuclear BSAP expression in mantle zone B cells, less intense reactivity in follicular center B cells, and no expression in cells of the T-cell-rich zones. Monocytoid B cells showed weak expression, whereas plasma cells and extrafollicular large transformed B cells were negative. Of the 102 B-cell NHLs, 83 (81%) demonstrated BSAP expression. All of the 13 (100%) B-cell chronic lymphocytic leukemias (B-CLLs), 21 of (100%) mantle cells (MCLs), and 20 of 21 (95%) follicular lymphomas (FLs) were positive. Moderate staining intensities were found in most B-CLL and FL cases, whereas most MCLs showed strong reactions, paralleling the strong reactivity of nonmalignant mantle cells. Eight of 12 (67%) marginal zone lymphoma cases showed negative or low BSAP levels, and 17 of 24 (71%) large B-cell lymphomas displayed moderate to strong expression. None of the 23 T- and null-cell lymphomas reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic predominance and 5 of 14 (36%) classical cases showed weak nuclear or nucleolar BSAP reactions in a fraction of the tumor cells. Western blot analysis showed a 52-kD BSAP band in B-cell lines, but not in non-B-cell or plasma cell lines. We conclude that BSAP expression is largely restricted to lymphomas of B-cell lineage and that BSAP expression varies in B-cell subsets and subtypes of B-cell NHL. The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. This is a US government work. There are no restrictions on its use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694719

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.

Authors:  Franziska C Eberle; Joo Y Song; Liqiang Xi; Mark Raffeld; Nancy Lee Harris; Wyndham H Wilson; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

3.  Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain.

Authors:  Edward Grimley; Chenzhong Liao; Egon J Ranghini; Zaneta Nikolovska-Coleska; Gregory R Dressler
Journal:  ACS Chem Biol       Date:  2017-01-24       Impact factor: 5.100

4.  Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas.

Authors:  Cigdem Atayar; Sibrand Poppema; Tjasso Blokzijl; Geert Harms; Marcel Boot; Anke van den Berg
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

5.  Characterization of the B lymphocyte-induced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter.

Authors:  C Tunyaplin; M A Shapiro; K L Calame
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

6.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

8.  Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India.

Authors:  Nidhi Johri; Shashikant C U Patne; Mallika Tewari; Mohan Kumar
Journal:  J Clin Diagn Res       Date:  2016-08-01

9.  2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated impairment of B cell differentiation involves dysregulation of paired box 5 (Pax5) isoform, Pax5a.

Authors:  Dina Schneider; Maria A Manzan; Robert B Crawford; Weimin Chen; Norbert E Kaminski
Journal:  J Pharmacol Exp Ther       Date:  2008-05-15       Impact factor: 4.030

10.  PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Authors:  Rajani Kanteti; Vidya Nallasura; Sivakumar Loganathan; Maria Tretiakova; Todd Kroll; Soundararajan Krishnaswamy; Leonardo Faoro; Philip Cagle; Aliya N Husain; Everett E Vokes; Deborah Lang; Ravi Salgia
Journal:  Lab Invest       Date:  2009-01-12       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.